These Phase 1 randomized, double-blind, placebo controlled, single and multiple dose studies evaluated the safety and tolerability, PK, immunogenicity, and PD of the anti-tau monoclonal antibody JNJ-63733657 in healthy participants and participants with prodromal or mild AD. The gene discussed is MAPT; the disease is Alzheimer disease.